The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemia

Chronic myeloid leukemia (CML) treatment has been improved by tyrosine kinase inhibitors (TKIs) such as imatinib mesylate (IM) but various factors can cause TKI resistance in patients with CML. One factor which contributes to TKI resistance is a germline intronic deletion polymorphism in the BCL2-li...

Descripción completa

Detalles Bibliográficos
Autores principales: Rauzan, Muhammad, Chuah, Charles T. H., Ko, Tun Kiat, Ong, S. Tiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354438/
https://www.ncbi.nlm.nih.gov/pubmed/28301600
http://dx.doi.org/10.1371/journal.pone.0174107

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354438/
https://www.ncbi.nlm.nih.gov/pubmed/28301600
http://dx.doi.org/10.1371/journal.pone.0174107

Ejemplares similares